Aurobindo Pharma rises 2% on USFDA final nod for Esomeprazole capsules
The company has received final approval from the US Food & Drug Administration (USFDA) to manufacture Esomeprazole Magnesium Delayed-Release Capsules OTC, 20mg.
Moneycontrol News
Shares of Aurobindo Pharma rose 2 percent intraday Tuesday as the company has received final approval to manufacture Esomeprazole Magnesium Delayed-release capsules.
The company has received final approval from the US Food & Drug Administration (USFDA) to manufacture Esomeprazole Magnesium Delayed-Release Capsules OTC, 20mg.
Esomeprazole Magnesium Delayed-Release Capsules OTC is a therapeutic equivalent generic version of AstraZeneca's Nexium 24HR capsules.
Nexium 24HR capsules are indicated to treat frequent heartburn and the product will be launched immediately.
This is the 127 ANDA (including 23 tentative approvals) to be approved out of Unit VII formulation facility in Hyderabad, India used for manufacturing oral products.
The company now has a total of 335 ANDA approvals (296 final approvals including 16 from Aurolife Pharma LLC and 39 tentative approvals) from USFDA.
At 11:14 hrs Aurobindo Pharma was quoting at Rs 768.05, up Rs 10.45, or 1.38 percent on the BSE.
Posted by Rakesh Patil
